Genetic Resilience: Nature's Blueprint for Prevention

We don't ask what makes people sick. We discover why some people stay well — despite the odds.

Traditional approach: What makes people sick

Halia's approach: Why people stay well

Outcome:
Faster, higher-confidence resilience-driven discovery

Discover Our Paradigm Shift
What is Genetic Resilience?

Uncovering Nature's
Built-In Defenses

At Halia Therapeutics, we shift the paradigm from treating illness to understanding resilience. Using population-scale pedigrees and genetic data, we uncover protective factors that help some individuals resist disease - even with high-risk genotypes or environmental triggers.

GENMOR: Pinpointing Nature's Protective Variants

Process Flow:

  1. Leverage UPDB genealogies and health records
  2. Identify disease-discordant families
  3. Perform genome-wide comparative analysis

Benefits:

  1. Uncovers resilience loci like RAB10
  2. Yields novel, biology-backed drug targets
  3. Enables proactive prevention strategies

Our Resilience-First
Clinical Programs

Alzheimer's

Some APOE4 carriers avoid Alzheimer's due to protective mutations. Halia identified and is targeting RAB10 based on these findings.

MIDS

Resilience variants show immune system restoration via NEK7 inhibition, forming the foundation for HT-6184.

Obesity

In preclinical models, HT-6184 enhances semaglutide efficacy while preserving lean mass.

Performance Metrics

Time-to-Phase 2B: ⅓ industry averageSignificant cost savings per program

Alzheimer's

Some APOE4 carriers avoid Alzheimer's due to protective mutations. Halia identified and is targeting RAB10 based on these findings.

MIDS

Resilience variants show immune system restoration via NEK7 inhibition, forming the foundation for HT-6184.

Obesity

In preclinical models, HT-6184 enhances semaglutide efficacy while preserving lean mass.

Performance Metrics

Time-to-Phase 2B: ⅓ industry averageSignificant cost savings per program

Re-Targeting Resilience
at Scale

GENMOR-AI™ empowers rapid, iterative discovery

3-Step Process:

  1. Integrate genomic and phenomic data
  2. Al-driven interaction modeling
  3. Automated prioritization of resilience factors

Benefits:

  • Reduces discovery timelines by ≥50%
  • Continuously refines hypotheses
  • Feeds top targets directly into GENMOR workflows

This is the Company AI Was Built For

Five Core Capabilities:

  1. Data Integration: Al synthesizes multi-modal datasets Pattern

  2. Detection: Deep learning finds missed protective patterns

  3. Speed: Fast, iterative retraining

  4. Precision: Resilient families reduce biological noise

  5. Scalability: Works across Alzheimer's, oncology, and metabolic disease

The Future of
Resilience-First
Medicine

We're building a next-generation drug development model — one that start with nature's own solutions. From genomic analysis to clinical translation, Halia's approach turn insights from resilient individuals into powerful therapies for everyone.

30%

Greater weight loss was achieved when HT-6184 was combined with semaglutide vs. semaglutide alone in preclinical models

30%

Of Alzheimer's patients carry APOEA — Halia's HT-4253 targets protective variants that may delay or prevent onset

10-20%

Of people over 70 carry CHIP mutations, increasing cancer and cardiovascular risk — targeting NEK7 may help mitigate this